Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Holt

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|September 29, 2005
ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effectsMichael J Watson, Jonathon D S Holt, Scott J O'Neill, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 16, 2005
DPI-221 [4-((alpha-s)-alpha-((2s,5r)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: a novel nonpeptide delta receptor agonist producing increased micturition interval in normal ratsJonathon D S Holt, Michael J Watson, Jane P Chang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 9, 2018
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced DyskinesiaElizabeth F Brigham, Tom H Johnston, Carl Brown, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|September 29, 2005
ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effectsMichael J Watson, Jonathon D S Holt, Scott J O'Neill, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 16, 2005
DPI-221 [4-((alpha-s)-alpha-((2s,5r)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: a novel nonpeptide delta receptor agonist producing increased micturition interval in normal ratsJonathon D S Holt, Michael J Watson, Jane P Chang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 9, 2018
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced DyskinesiaElizabeth F Brigham, Tom H Johnston, Carl Brown, et al.
Pageof 2